I Slept on Wolf's Memory Foam Hybrid Premium Firm Mattress for a Week and Was Impressed
This is really helpful for side sleepers in particular. The feel and firmness of the mattress are also right on target for achieving pressure relief and weight distribution for lumbar support. Too soft a mattress and your lower back bends into weird-feeling angles. As sleepers with back pain will tell you, even the slightest pressure applied to your lower back can be a means for a rough night of sleep. That being said, I think average and plus-size sleepers who are in that 150-pound-and-up range are best suited for this bed. If you have really serious hip pain or have a smaller build, this bed's firmness and pressure-relieving layers are most likely not going to agree with your joints.
Not all mattresses can achieve the right support level, but here is a rare instance where I felt confident sleeping on my stomach, back, and side. That's no small feat, and I can't understate that. I picked up on that right away on the first night of testing.
Throughout the duration of my time with the bed (which was a week, to be exact), I also came to appreciate the edge support, cooling, and motion isolation the construction offered. Edge support is just how it sounds—where a mattress makes sure you're not rolling off the sides in the middle of the night. Given that I love to sleep on the edge, as my two small dogs hog the rest of the bed, this is a feature I'm always acutely aware of while testing. I felt secure the entire time, and I had no issues sitting on the sides or bottom while getting in and out of bed, either. The Alpha Mattress
Photograph: Julia Forbes
I live in a humid climate that sticks around long after the sun has set. I had thinner, eucalyptus-based cooling sheets on the bed, which helped play to the performance of the Wolf's cooling cover. I could feel the coolness of the cover permeating through the sheets, and I didn't note one instance of overheating during testing. Motion transfer I also pay special attention to, because even with small dogs jumping in and out of bed or even with my husband who sleeps like a log, even slight movement wakes me up. One night the dogs were just trying to burn the midnight oil, but their incessant antics of trying to turn the bed into a trampoline park were unsuccessful. Slight vibrations were felt, but nothing that broke me out of my sleep trance—until someone barked at me to go outside.
I don't take it easy on my critical analysis of mattresses, which is why I don't land on the high score lightly. Wolf Mattress didn't just manage to hold its own, but it made its debut on my personal all-stars list. I love the value it delivers straight out of the box. The materials feel high-quality, the performance was top-tier, and the price was on target to match. Based on this experience, I'm excited to see all the things the company has planned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
WIRED
7 days ago
- WIRED
I Slept on Wolf's Memory Foam Hybrid Premium Firm Mattress for a Week and Was Impressed
For context, I usually sleep on the Nolah Evolution Hybrid (9/10, WIRED Recommends), which happens to be one of the best mattresses I've tested to date. The first thing I noticed with this bed was that the pressure relief was eerily similar to the Nolah's. Even with a more medium-firm surface, which I'd put right around a 6.5 out of 10, it wasn't uncomfortable against my hips or shoulders. This is really helpful for side sleepers in particular. The feel and firmness of the mattress are also right on target for achieving pressure relief and weight distribution for lumbar support. Too soft a mattress and your lower back bends into weird-feeling angles. As sleepers with back pain will tell you, even the slightest pressure applied to your lower back can be a means for a rough night of sleep. That being said, I think average and plus-size sleepers who are in that 150-pound-and-up range are best suited for this bed. If you have really serious hip pain or have a smaller build, this bed's firmness and pressure-relieving layers are most likely not going to agree with your joints. Not all mattresses can achieve the right support level, but here is a rare instance where I felt confident sleeping on my stomach, back, and side. That's no small feat, and I can't understate that. I picked up on that right away on the first night of testing. Throughout the duration of my time with the bed (which was a week, to be exact), I also came to appreciate the edge support, cooling, and motion isolation the construction offered. Edge support is just how it sounds—where a mattress makes sure you're not rolling off the sides in the middle of the night. Given that I love to sleep on the edge, as my two small dogs hog the rest of the bed, this is a feature I'm always acutely aware of while testing. I felt secure the entire time, and I had no issues sitting on the sides or bottom while getting in and out of bed, either. The Alpha Mattress Photograph: Julia Forbes I live in a humid climate that sticks around long after the sun has set. I had thinner, eucalyptus-based cooling sheets on the bed, which helped play to the performance of the Wolf's cooling cover. I could feel the coolness of the cover permeating through the sheets, and I didn't note one instance of overheating during testing. Motion transfer I also pay special attention to, because even with small dogs jumping in and out of bed or even with my husband who sleeps like a log, even slight movement wakes me up. One night the dogs were just trying to burn the midnight oil, but their incessant antics of trying to turn the bed into a trampoline park were unsuccessful. Slight vibrations were felt, but nothing that broke me out of my sleep trance—until someone barked at me to go outside. I don't take it easy on my critical analysis of mattresses, which is why I don't land on the high score lightly. Wolf Mattress didn't just manage to hold its own, but it made its debut on my personal all-stars list. I love the value it delivers straight out of the box. The materials feel high-quality, the performance was top-tier, and the price was on target to match. Based on this experience, I'm excited to see all the things the company has planned.
CNN
11-07-2025
- CNN
In what some call a ‘national movement,' more than a dozen states introduce menopause bills
There's a new wave of interest in improving menopause care in the United States – it's in books, on podcasts and dominating social media hashtags – and it's even generating new legislation across more than a dozen states. From New York to California, lawmakers are weighing whether to support more menopause training for clinicians or mandate comprehensive insurance coverage for menopause treatment. Advocates of such legislation argue that these changes could improve access to care and reduce the risk that menopause symptoms will be dismissed by providers. At least two dozen bills have been introduced across 15 states this year, according to data from Jennifer Weiss-Wolf, executive director of the Birnbaum Women's Leadership Center at the New York University School of Law, and her colleagues who have been tracking menopause legislation. Most of the legislation is related to insurance coverage for menopause care, awareness and education, clinician training or menopause in the workplace. When it comes to menopause care, there continues to be a 'lack of standardized treatment protocols' and 'inadequate insurance coverage for evidence-based therapies like hormone replacement,' Dr. Mary Claire Haver, an ob/gyn at the Mary Claire Wellness Clinic in Galveston, Texas, and author of the book 'The New Menopause,' said in an email. She hopes that some of the new legislation introduced this year – and future policies – may change that. Menopause is a natural phase of aging in which a woman has gone at least 12 consecutive months without a menstrual period due to a decline in her reproductive hormones. These hormonal changes can cause uncomfortable symptoms, including hot flashes, insomnia, vaginal and urinary problems, mood changes and weight gain, and can have long-term health implications. In the United States, an estimated 1.3 million women enter menopause each year, and most have symptoms. 'For decades, menopause has been overlooked in both clinical research and health care policy, largely because it affects women in midlife — a group that has historically been underrepresented and undervalued in medicine,' said Haver, who collaborated with Weiss-Wolf on developing A Citizen's Guide to Menopause Advocacy. 'Women in midlife are speaking out, demanding better care, and using their voices on platforms where they've historically been ignored,' she said. 'We're also seeing more female physicians, researchers, and public figures normalize the conversation around menopause — which is finally translating into policy discussions and workplace changes.' As the 2025 legislative session has come to an end in most states, some more recently introduced menopause bills may be up for action next year. Most of the bills may not become laws, but that's not a loss, said Weiss-Wolf, author of the book 'Periods Gone Public: Taking a Stand for Menstrual Equity.' 'This only sets us up for what I hope will be a really impactful, successful state legislative session in 2026,' she said. 'So, for me as an advocate, I'm not only marking success by bills passed, but just that the conversation has gotten to the point where state legislators are willing to step out on this issue.' Two bills introduced in March relate to raising awareness around menopause, according to Weiss-Wolf and her colleagues. One Illinois bill, passed in May, declares October 12-18 to be Menopause Awareness Week in the state. The other bill, introduced in Nevada, would have designated October as Menopause Awareness Month, but it was vetoed by the governor in June. Seven bills were introduced this year related to education, aiming to enable health care providers with more education about menopause treatment or requiring health departments to distribute educational resources for the public. One, in Maine, was signed by the governor and enacted last week. When it comes to enhancing menopause training for clinicians, California and New Jersey both introduced bills related to those themes this year. In California, legislation would require an assessment of physicians' education and training on menopause diagnosis and treatment. In New Jersey, the bill would permit up to three credits of continuing medical education on menopause to be used by providers to renew their licenses. Meanwhile, five bills have been introduced related to requiring insurance coverage for menopause care. One in New Jersey passed the Assembly, and one in Oregon is awaiting the governor's signature. 'This is absolutely a national movement, and the momentum is undeniable. It's not just happening in California — Washington State, Oregon, Illinois, and Louisiana have all had bills either introduced or successfully passed in this space, with most of them looking to create similar insurance coverage mandates,' California Assemblymember Rebecca Bauer-Kahan said in an email. This year, Bauer-Kahan introduced Assembly Bill 432, which would mandate coverage for menopause evaluation and treatment options, among other orders. She said the bill was born out of her own experience of having perimenopausal symptoms and being dismissed when she asked her doctors for care. 'I didn't know what was happening to me. So like many people would, I went to my internist. She said I was fine. But I knew I wasn't fine. I knew something was fundamentally wrong with my body. I went to my ob/gyn. Here I am, a woman in my mid-40s, telling my doctor that my brain isn't working properly, and once again, I was dismissed as 'fine,' ' Bauer-Kahan said in the email. 'Women are over half the population, and yet our healthcare system fails to provide us with the care we need as we age,' she wrote. 'This legislation closes the care gap, ensuring that menopause is treated as the central health need it is, not as an afterthought. We deserve comprehensive coverage and informed medical care, just like any other stage of life.' A Rhode Island bill related to menopause in the workplace was signed into law last week, making it the first state to enact workplace protections for menopausal women – and more could be coming. Legislation introduced this year in New York and New Jersey aims to address menopause in the workplace by preventing discrimination, extending workplace protections and requiring employers to allow remote work or paid leave for employees with symptoms. Then there are a few other bills, such as in Massachusetts and New York, related to a combination of menopause issues. 'What's particularly encouraging is that menopause crosses party lines,' Bauer-Kahan said. 'On the Assembly floor, my bill passed 70-1. This isn't a political issue; it's about recognizing that half our population deserves proper healthcare.' Of the menopause bills introduced this year so far, 11 are in committee, seven have passed in some capacity with four to be enacted, five either were vetoed or died in committee and one was amended. What appears to be a renewed interest in menopause policy comes after more than two decades of 'silence' around menopause, said Dr. Sharon Malone, chief medical adviser at Alloy Women's Health and author of the book 'Grown Woman Talk.' In 2002, a national Women's Health Initiative study was terminated early after it linked hormone therapy for menopause to an increased risk of breast cancer. The Women's Health Initiative is an ongoing research project conducted by the US National Institutes of Health, focused on preventing disease in older women. Although the objective of the study was never to test the use of menopausal hormone therapy to treat symptoms of menopause, and it was halted early without definitive findings, it had long-lasting impacts on menopause care in the United States. Many women stopped using hormone therapy because of the study, and some practitioners no longer recommended it for their patients. But since then, a growing body of research has found that the benefits of hormone therapy outweigh any small risks for most women with menopause symptoms, emphasizing that hormone therapy can be an effective way to treat symptoms because it helps replace the hormones that the body stops making during menopause. Next week, the US Food and Drug Administration plans to hold a public discussion about menopause and hormone replacement therapy for women. The panel will include FDA Commissioner Dr. Marty Makary and Dr. Sara Brenner, the agency's principal deputy commissioner, who are expected to discuss treatments, education and comprehensive care beyond managing symptoms. Years of physician training and research around menopause care and hormone therapy was lost after 2002, Malone said. 'We are still digging ourselves out of a hole of the past 23 years, understanding that there are 23 years of physicians who have not been trained in how to treat and how to deal with conditions of women during menopause. So, if you graduated from medical school and trained any time after the year 2000, you probably were never even given a fair discussion of hormone therapy,' Malone said. 'And the biggest problem that we're facing now is that there's 23 years of research that wasn't done because everybody took the Women's Health Initiative as the definitive answer, which it was not,' she said. 'If I could wave a magic wand, what I would do is eliminate the disinformation that's out there about hormone therapy.' Dr. Monica Christmas, an associate professor of obstetrics and gynecology at the University of Chicago and associate medical director for The Menopause Society, finished medical school and started residency around the time the Women's Health Initiative findings were released in the early 2000s. 'At that time, there was a lot of fear and trepidation around hormone therapy in particular,' said Christmas, who also serves as director of the menopause program at UChicago Medicine. 'I was fortunate that where I did residency, here in Chicago, I was trained by gynecologists who managed menopausal patients. Looking back on it now, they were probably menopausal themselves,' she said. 'And they were still fairly comfortable with prescribing hormone therapy and really understood what later the data came back to show – that, yes, there's this window of opportunity where the benefits seem to outweigh the risks for most people. That window is under the age of 60 or within 10 years of the onset of menopause.' Increased menopause awareness and additional education for providers are important issues, Christmas said, but she views extended coverage for menopause care and the treatment of symptoms as the most pressing matter. 'Physicians can have a wealth of knowledge, which they do; however, if the person's insurance doesn't cover treatment, then it stops there,' Christmas said, adding that it's not fair to put responsibility on health care practitioners alone to change the landscape of menopause care. 'The policy focus needs to be on ensuring comprehensive and equitable access to medical care, resources for innovative research and new treatment options, and supportive work conditions.'
